Form 4: 10x Genomics CEO Sells $289K in Shares

10x Genomics CEO Serge Saxonov sold 15,000 shares of Class A Common Stock for approximately $289,000 through a pre-arranged 10b5-1 trading plan.

Summary

• Serge Saxonov, CEO and Director of 10x Genomics, Inc. (TXG), reported sales of Class A Common Stock.
• On March 23, 2026, 10,000 shares were sold at a weighted average price of $19.1297 per share, totaling approximately $191,297.
• On March 24, 2026, an additional 5,000 shares were sold at a weighted average price of $19.5223 per share, totaling approximately $97,611.50.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 29, 2025.
• Following these sales, Saxonov directly beneficially owns 1,172,273 shares of Class A Common Stock.
• Indirect beneficial ownership of Class A Common Stock includes 27 shares via the Andromeda Trust, 213,250 shares via the Y/S Descendants' Trust, and 71,644 shares via the Y/S Pot Trust, all for which Saxonov serves as trustee.
• Saxonov also directly beneficially owns 1,100,927 shares of Class B Common Stock, convertible into Class A Common Stock.
• Indirect beneficial ownership of Class B Common Stock includes 180,938 shares via the Sirius Trust and 1,750,000 shares across several irrevocable trusts, for which Saxonov is the sole trustee.
• Earlier transfers on March 3, 2026, included 13,644 Class A shares to the Y/S Pot Trust and 91,113 Class B shares to the Sirius Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. While insider selling can sometimes be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sales are based on new, adverse material information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• The CEO sold a total of 15,000 shares of Class A Common Stock, which could be perceived as a reduction in direct personal stake in the company.

Industry Context

StockSavvy.ai notes that insider selling, even when pre-scheduled via a 10b5-1 plan, is a common occurrence for executives managing personal finances and diversifying portfolios. In the highly dynamic genomics and biotechnology sector, such transactions are generally viewed with less alarm if they are part of a long-term plan rather than an ad-hoc sale.

Related Party Transactions

• Transfer of 13,644 shares of Class A Common Stock to the Y/S Pot Trust, for which the Reporting Person serves as trustee.
• Transfer of 91,113 shares of Class B Common Stock to the Sirius Trust, for which the Reporting Person serves as trustee.
• Indirect beneficial ownership of Class A Common Stock through the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, all with the Reporting Person as trustee.
• Indirect beneficial ownership of Class B Common Stock through the Sirius Trust and several 2018 Irrevocable Trusts, all with the Reporting Person as sole trustee.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be interpreted by some as a slight reduction in management's direct alignment with shareholder interests, though the 10b5-1 plan context lessens this concern.

Key Dates

Recommendation

The insider sales by the CEO, while a reduction in direct holdings, were conducted under a pre-arranged 10b5-1 plan. This suggests a planned financial management strategy rather than a reaction to new, negative company-specific news. The filing itself does not provide new fundamental information about the company's operations or future prospects that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting further operational updates.

Keywords

10x Genomics, TXG, Serge Saxonov, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Beneficial Ownership, Class A Common Stock, Class B Common Stock